Modality
ERT
MOA
BCMA ADC
Target
GIP-R
Pathway
Complement
Ovarian CaCervical CaMDD
Development Pipeline
Preclinical
~Jan 2011
→ ~Apr 2012
Phase 1
~Jul 2012
→ ~Oct 2013
Phase 2
~Jan 2014
→ ~Apr 2015
Phase 3
~Jul 2015
→ ~Oct 2016
NDA/BLA
Jan 2017
→ Nov 2030
NDA/BLACurrent
NCT04771638
171 pts·Cervical Ca
2025-10→2025-06·Not yet recruiting
NCT05806105
1,503 pts·Cervical Ca
2017-01→2030-11·Not yet recruiting
1,674 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-0510mo agoPh3 Readout· Cervical Ca
2030-11-264.7y awayPh3 Readout· Cervical Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2025-06-05 · 10mo ago
Cervical Ca
Ph3 Readout
2030-11-26 · 4.7y away
Cervical Ca
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04771638 | NDA/BLA | Cervical Ca | Not yet recr... | 171 | HbA1c |
| NCT05806105 | NDA/BLA | Cervical Ca | Not yet recr... | 1503 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |